SCHEMBL16993979

SCHEMBL16993979

O=C(NC(Cc1ccccc1)C(=O)Nc1cccc2ncccc12)c1ccccc1Cl

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PABPC1 P11940 3/20 0.66
▸ EIF4H Q15056 3/20 0.66
▸ ALDH1A1 P00352 3/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ USP30 Q70CQ3 3/20 0.52
▸ MAPT P10636 2/20 0.52
▸ CTSV O60911 1/20 0.51
▸ CTSL P07711 1/20 0.51
▸ CTSS P25774 1/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ NSD2 O96028 1/20 0.48
▸ ITGB1 P05556 1/20 0.48
▸ ITGA4 P13612 1/20 0.48
▸ CLK1 P49759 1/20 0.48
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16999319 1.00 PABPC1 (0.66) PABPC1EIF4HALDH1A1KDM4EUSP30
SCHEMBL24862952 0.89 PABPC1 (0.53) PABPC1EIF4HALDH1A1KDM4EUSP30
SCHEMBL16999703 0.88 KDM4E (0.53) PABPC1EIF4HALDH1A1KDM4EUSP30
SCHEMBL16999362 0.88 KDM4E (0.53) PABPC1EIF4HALDH1A1KDM4EUSP30
SCHEMBL16994059 0.88 KDM4E (0.53) PABPC1EIF4HALDH1A1KDM4EUSP30
SCHEMBL16994018 0.88 KDM4E (0.53) PABPC1EIF4HALDH1A1KDM4EUSP30
SCHEMBL16994008 0.87 USP30 (0.59) PABPC1EIF4HALDH1A1KDM4EUSP30
SCHEMBL16999330 0.87 USP30 (0.59) PABPC1EIF4HALDH1A1KDM4EUSP30
SCHEMBL19976933 0.83 PABPC1 (0.73) PABPC1EIF4HALDH1A1KDM4EMAPT
SCHEMBL16993880 0.82 HSPA5 (0.64) ALDH1A1KDM4EUSP30MAPTCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3102193-B1 ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES UNIV RUTGERS (US) 2023-01-11 — — EP disclosed
US-9919998-B2 Antibacterial agents: Nα-aroyl-N-aryl-phenylalaninamides RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2018-03-20 — — US disclosed
EP-3102193-A1 ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES Rutgers, The State University of New Jersey (US) 2016-12-14 — — EP disclosed
US-20160347708-A1 ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2016-12-01 — — US disclosed
WO-2015120320-A1 ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2015-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160347708-A1 ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES TYR, NAT1, AANAT PABPC1 891/4885EIF4H 1753/4885ALDH1A1 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback